Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Current Leases (2020 - 2026)

Cryo Cell International's Current Leases history spans 7 years, with the latest figure at $426254.0 for Q1 2026.

  • Quarterly results put Current Leases at $426254.0 for Q1 2026, down 5.7% from a year ago — trailing twelve months through Feb 2026 was $426254.0 (down 5.7% YoY), and the annual figure for FY2025 was $430221.0, changed 0.44%.
  • Current Leases for Q1 2026 was $426254.0 at Cryo Cell International, down from $430221.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $465231.0 in Q2 2025 to a low of $221062.0 in Q3 2023.
  • The 5-year median for Current Leases is $315042.0 (2022), against an average of $339099.0.
  • The sharpest move saw Current Leases decreased 28.67% in 2023, then soared 89.79% in 2024.
  • Year by year, Current Leases stood at $297691.0 in 2022, then fell by 24.19% to $225686.0 in 2023, then soared by 89.79% to $428334.0 in 2024, then increased by 0.44% to $430221.0 in 2025, then fell by 0.92% to $426254.0 in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $426254.0, $430221.0, and $434604.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.